Kytril

Granisetron, the active ingredient in Kytril, is a 5-HT3 receptor antagonist presented as an oral dosage form for oral use. It treats and prevents nausea and vomiting associated with chemotherapy and postoperative settings.

GNH USA supplies Kytril as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Kytril (granisetron) is used to manage nausea and vomiting mediated by serotonin 5‑HT3 receptors.

- Chemotherapy‑induced nausea and vomiting: prevents and reduces acute and delayed episodes in cancer patients receiving emetogenic chemotherapy. - Postoperative nausea and vomiting: lowers the incidence of nausea and vomiting after surgical procedures. - Radiation‑induced nausea and vomiting: helps control nausea associated with therapeutic radiation.

Granisetron may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Dizziness: occasional light‑headedness. - Fatigue: feeling of tiredness. - Diarrhoea: loose stools. - Abdominal pain: mild cramps.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmia. - Severe allergic reactions: rash, itching, swelling. - Anaphylaxis: rare but life‑threatening hypersensitivity. - Serotonin syndrome: rare when combined with other serotonergic agents. - Severe hypotension: sudden drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm.

Before prescribing Kytril, clinicians should consider several safety factors.

- Cardiac assessment: evaluate baseline ECG and QT interval. - Hepatic impairment: use with caution in patients with liver dysfunction. - Renal impairment: adjust dosing if significant renal failure is present. - Hypersensitivity: avoid in individuals with known allergy to granisetron or other 5‑HT3 antagonists. - Concomitant QT‑prolonging drugs: monitor closely for additive cardiac effects. - Store at ambient temperature (below 25°C): keep in the original container, protect from moisture and light.

Granisetron can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other QT‑prolonging agents: increased risk of cardiac arrhythmia. - Potent CYP3A4 inhibitors: may raise granisetron plasma levels. - Concurrent 5‑HT3 antagonists: no added benefit and higher side‑effect risk.

Moderate Interactions (Monitor Closely): - Dexamethasone: enhanced antiemetic effect, monitor for steroid‑related side effects. - Opioids: heightened risk of constipation. - Anticholinergic drugs: may increase dry mouth and blurred vision.